Actavis Sues Sandoz, Hetero Over Generic Prostate Drug

Law360, New York (June 19, 2013, 1:08 PM EDT) -- Kissei Pharmaceutical Co. Ltd. and Actavis Inc. said Monday in virtually identical suits filed in Delaware federal court that Sandoz Inc. and Hetero Labs Ltd. infringed a patent for their enlarged-prostate drug by seeking approval for generic forms of the treatment.

Sandoz and Hetero unlawfully filed abbreviated new drug applications with the U.S. Food and Drug Administration to market 4- and 8-milligram silodosin tablets before the expiration of the patent for Rapaflo, which is sold by Actavis subsidiary Watson Laboratories Inc., according to the suit....
To view the full article, register now.

Related

Sections

Case Information

Case Title

Kissei Pharmaceutical Co. Ltd. et al v. Hetero USA Inc., et al.


Case Number

1:13-cv-01091

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

June 17, 2013


Case Title

Kissei Pharmaceutical Co. Ltd. et al v. Sandoz Inc.


Case Number

1:13-cv-01092

Court

Delaware

Nature of Suit

Patent

Judge

Leonard P. Stark

Date Filed

June 17, 2013

Law Firms

Companies

Government Agencies

Patents

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.